Literature DB >> 18599489

Birth defects among infants born to women who received anthrax vaccine in pregnancy.

Margaret A K Ryan1, Tyler C Smith, Carter J Sevick, William K Honner, Rosha A Loach, Cynthia A Moore, J David Erickson.   

Abstract

In response to bioterrorism threats, anthrax vaccine has been used by the US military and considered for civilian use. Concerns exist about the potential for adverse reproductive health effects among vaccine recipients. This retrospective cohort evaluated birth defects, in relation to maternal anthrax vaccination, among all infants born to US military service women between 1998 and 2004. Department of Defense databases defined maternal vaccination and infant diagnoses; multivariable regression models described potential associations between anthrax vaccination and birth defects in liveborn infants. Among 115,169 infants born to military women during this period, 37,140 were born to women ever vaccinated against anthrax, and 3,465 were born to women vaccinated in the first trimester of pregnancy. Birth defects were slightly more common in first trimester-exposed infants (odds ratio = 1.18, 95% confidence interval: 0.997, 1.41) when compared with infants of women vaccinated outside of the first trimester, but this association was statistically significant only when alternative referent groups were used. Although the small observed association may be unlikely to represent a causal relation between vaccination in early pregnancy and birth defects, this information should be considered when making decisions about administering anthrax vaccine to pregnant women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599489     DOI: 10.1093/aje/kwn159

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  8 in total

1.  Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Authors:  Tracy Pondo; Charles E Rose; Stacey W Martin; Wendy A Keitel; Harry L Keyserling; Janiine Babcock; Scott Parker; Robert M Jacobson; Gregory A Poland; Michael M McNeil
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

2.  Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.

Authors:  Karina Ramirez; Yanina Ditamo; James E Galen; Les W J Baillie; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

3.  Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Authors:  Pedro L Moro; Janet Cragan; Paige Lewis; Lakshmi Sukumaran
Journal:  Birth Defects Res       Date:  2017-07-17       Impact factor: 2.344

4.  Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.

Authors:  Dana Meaney-Delman; Marianne E Zotti; Andreea A Creanga; Lara K Misegades; Etobssie Wako; Tracee A Treadwell; Nancy E Messonnier; Denise J Jamieson
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

Review 5.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

6.  Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should Have Been) Learned from Excluding Immunization with the Ebola Vaccine during Pregnancy and Lactation.

Authors:  David A Schwartz
Journal:  Vaccines (Basel)       Date:  2018-12-04

Review 7.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

8.  A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.

Authors:  Saugata Majumder; Shreya Das; Vikas Somani; Shivakiran S Makam; Kingston J Joseph; Rakesh Bhatnagar
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.